other HCV Information

HISTORY OF HCV

GLOSSARY/ABBREVIATIONS

LIVER FUNCTIONS

QUESTIONS ABOUT HCV

EXTRAHEPATIC CONDITIONS

SYMPTOMS

TRANSMISSION

SEXUAL TRANSMISSION

HCV BLOOD TESTS/LABS

LABS ON TREATMENT

BIOPSY RESULTS

ALTERNATIVE TO BIOPSY

STILL NEED A BIOPSY ?

ON BIOPSY WHAT DOES THE STAGE MEAN AND WHAT DOES THE GRADE ME ?

STAGES/LIVER DISEASE

FIBROSIS

CIRRHOSIS

TRANSPLANTS

LIVER CANCER

GENOTYPES

VIRAL LOAD

PEGASYS/ PEGINTRON

INFERGEN

HELP/SIDE EFFECTS

DRUG INTERACTIONS

NUTRITION  & HCV

TREATMENT STORIES

FIRST SHOT

INTERVIEWS

FIND A DOCTOR

FINANCIAL AID/MED ETC

SUPPORT GROUPS/TRANSPLANTS

HCV SUPPORT GROUPS

PICTURES Of OUR FRIENDS

INFORMATIONAL LINKS

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

This Web Site is committed to the memory of Janis Morrow.

Human liver   

38th Annual Meeting of the European Association for the Study of the Liver
Istanbul, Turkey. March 28-April 1, 2003

Index

  Page One

OUTCOME OF LIVING DONOR LIVER TRANSPLANTATION (LDLT) : GRAFT SURVIVAL IS POOR ESPECIALLY IN HCV RECIPIENTS

  A RANDOMISED DOUBLE-BLIND PHASE II STUDY OF LAMIVUDINE (LAM) COMPARED TO LAMIVUDINE PLUS ADEFOVIR DIPIVOXIL (ADV) FOR TREATMENT NÁVE PATIENTS WITH CHRONIC HEPATITIS B (CHB) : WEEK 52 ANALYSIS
  SIMVASTATIN AMMELIORATES THE INCREASED HEPATIC VASCULAR TONE IN PATIENTS WITH CIRRHOSIS
   

Page two

  TENOFOVIR EFFECTIVELY INHIBITS VIRAL REPLICATION IN DIFFERENT PATIENT GROUPS WITH LAMIVUDINE RESISTANT HBV INFECTION
  LIVER FIBROSIS REGRESSES BETTER WITH PEGINTERFERON ALPHA AND URSODEOXYCHOLIC ACID TREATMENT THAN SPONTANEOUS RECOVERY
  EFFECT OF HBV AND HCV COINFECTION ON ANTI-VIRAL T CELL RESPONSES
  A RANDOMIZED CONTROLLED TRIAL OF PEGYLATED-INTERFERON ALPHA-2B + RIBAVIRIN VS INTERFERON ALPHA-2B + RIBAVIRIN IN HIV CO-INFECTED PATIENTS

Page three

COMBINATION OF PEGYLATED INTERFERON AND LAMIVUDINE IS SUPERIOR TO LAMIVUDINE MONOTHERAPY IN THE TREATMENT OF CHRONIC HEPATITIS B - A RANDOMIZED TRIAL

  PREDICTORS OF VIROLOGIC RESPONSE IN COMBINATION THERAPY WITH INTERFERON (IFN) ALFA 2B PLUS RIBAVIRIN OF RECURRENT HEPATITIS C AFTER LIVER TRANSPLANTATION (LT)
  PREDCTIVE FACTORS OF HCC RECURRENCE AFTER LIVER TRANSPLANTATION (OLT) : AN INTERIM ANALYSIS
  Factors Associated With recurrence After Liver transplantation For Hepatocellular Carcinoma
  A STUDY OF THE PRESENCE OF HCV RNA IN SEMEN OF PATIENTS WITH CHRONIC HCV INFECTION

Page Four

  EFFICACY OF PEGINTERFERON ALFA-2A (40KD) (PEGASYS) PLUS RIBAVIRIN FOR 24 WEEKS IN GENOTYPE 1 PATIENTS WITH CHRONIC HEPATITIS C FOLLOWED BY MONO OR COMBINATION THERAPY FOR 22 WEEKS: PRELIMINARY ANALYSIS OF AN OPEN, MULTICENTER, RANDOMIZED TRIAL
  Entecavir for HBV in Lamivudine Failures
  EFFICIENCY OF DNA VACCINE IN ASSOCIATION WITH LAMIVUDINE FOR CHRONIC HEPATITIS B THERAPY
  THE EFFECT OF PEGINTERFERON ALFA-2A (40 KD) ON LIVER HISTOLOGY IN CHRONIC HEPATITIS C: A META-ANALYSIS OF INDIVIDUAL PATIENTS DATA
  Clevudine, New Drug for HBV
  PHARMACOKINETICS OF PEGINTERFERON ALFA-2A (40KD, PEGASYS) COMPARED TO PEGINTERFERON ALFA-2B (12KD, PEGINTRON) IN NAIVE PATIENTS WITH CHRONIC HEPATITIS C (CHC)
  Study Suggests More Than 48 Weeks Therapy for Patients with high baseline viral loads, HCV genotype 1, and cirrhosis may be necessary
  72 weeks HCV Therapy (PegIFN/RBV): is it effective?

 

 

 

 

 

 

 

 

 


Design downloaded from Zeroweb.org: Free website templates, layouts, and tools.